Index -
P/E -
EPS (ttm) -4.30
Insider Own 26.35%
Shs Outstand 26.45M
Perf Week -1.79%
Market Cap 51.19M
Forward P/E -
EPS next Y -2.71
Insider Trans 2.24%
Shs Float 19.69M
Perf Month 11.99%
Income -131.56M
PEG -
EPS next Q -0.68
Inst Own 56.22%
Short Float 4.86%
Perf Quarter -65.68%
Sales 4.15M
P/S 12.33
EPS this Y 64.31%
Inst Trans 85.92%
Short Ratio 3.13
Perf Half Y -69.79%
Book/sh -0.24
P/B -
EPS next Y -30.50%
ROA -91.46%
Short Interest 0.96M
Perf Year -51.15%
Cash/sh 2.95
P/C 0.65
EPS next 5Y -
ROE -393.39%
52W Range 1.43 - 8.17
Perf YTD -75.42%
Dividend Est. -
P/FCF -
EPS past 5Y 21.16%
ROI -253.91%
52W High -76.56%
Beta 1.58
Dividend TTM -
Quick Ratio 3.46
Sales past 5Y 128.79%
Gross Margin 62.39%
52W Low 33.92%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 3.46
EPS Y/Y TTM 22.30%
Oper. Margin -2835.68%
RSI (14) 38.64
Volatility 12.22% 9.16%
Employees 68
Debt/Eq -
Sales Y/Y TTM -53.52%
Profit Margin -3171.70%
Recom 1.00
Target Price 8.75
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 54.27%
Payout -
Rel Volume 0.41
Prev Close 1.98
Sales Surprise -100.00%
EPS Surprise 23.12%
Sales Q/Q -100.00%
Earnings Jul 31 BMO
Avg Volume 306.17K
Price 1.91
SMA20 13.78%
SMA50 -46.73%
SMA200 -64.12%
Trades
Volume 110,768
Change -3.28%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-04-20 Upgrade
H.C. Wainwright
Neutral → Buy
$11 → $15
Sep-22-20 Initiated
Alliance Global Partners
Buy
$18
Jan-17-20 Downgrade
Wedbush
Outperform → Neutral
Mar-08-19 Resumed
JMP Securities
Mkt Outperform
$18
Feb-14-19 Resumed
Oppenheimer
Outperform
$13
Nov-05-18 Upgrade
ROTH Capital
Neutral → Buy
Mar-13-18 Reiterated
Wedbush
Outperform
$11 → $13
Oct-31-17 Resumed
Piper Jaffray
Overweight
$30
Oct-23-17 Initiated
ROTH Capital
Neutral
$15
Aug-10-17 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Sep-12-24 07:00PM
07:00PM
Aug-27-24 07:00AM
Aug-14-24 10:19AM
09:35AM
09:41AM
Loading…
Aug-13-24 09:41AM
09:13AM
(Pharmaceutical Technology)
Aug-12-24 04:15PM
Aug-05-24 09:55AM
Jul-31-24 07:30AM
Jul-24-24 07:00AM
Jul-17-24 11:24AM
08:00AM
Jun-13-24 07:00AM
May-15-24 03:03AM
01:14AM
Loading…
01:14AM
(Thomson Reuters StreetEvents)
May-14-24 10:52AM
07:30AM
May-07-24 09:00AM
07:00AM
May-01-24 10:01AM
Apr-10-24 09:49AM
08:30AM
Apr-09-24 07:00AM
Apr-02-24 04:30PM
(Business Wire) -8.04%
+7.44%
Mar-28-24 10:06AM
Mar-27-24 11:53AM
07:30AM
Mar-25-24 07:00AM
Mar-20-24 07:00AM
07:00AM
Loading…
Feb-27-24 07:00AM
Jan-31-24 04:00PM
Jan-19-24 10:43AM
Jan-18-24 12:00PM
Jan-17-24 08:50AM
Jan-16-24 12:00PM
09:55AM
Jan-11-24 08:48AM
Jan-08-24 07:00AM
Jan-03-24 11:03PM
Dec-19-23 07:27AM
Dec-07-23 09:44AM
Dec-06-23 07:00AM
Dec-03-23 04:17PM
Nov-21-23 07:30AM
Nov-15-23 01:08PM
Nov-14-23 07:30AM
Nov-07-23 07:30AM
Oct-02-23 08:45AM
Sep-07-23 04:30PM
Aug-08-23 09:49PM
(Thomson Reuters StreetEvents)
09:05AM
07:30AM
Aug-04-23 04:30PM
Aug-01-23 07:30AM
Jul-27-23 06:29AM
(American City Business Journals)
Jul-21-23 05:40PM
Jul-05-23 04:30PM
Jun-22-23 08:14PM
Jun-13-23 08:00AM
Jun-08-23 07:30AM
Jun-01-23 04:30PM
May-25-23 05:05PM
08:44AM
May-13-23 10:15AM
May-10-23 10:08PM
(Thomson Reuters StreetEvents) +10.29%
08:45AM
07:30AM
May-09-23 07:00AM
May-07-23 08:40PM
May-03-23 07:30AM
May-02-23 07:00AM
Mar-06-23 09:48AM
Mar-04-23 07:08AM
Mar-02-23 10:02PM
(Thomson Reuters StreetEvents)
09:35AM
07:30AM
Feb-28-23 07:30AM
Feb-23-23 07:30AM
Feb-09-23 04:05PM
Feb-01-23 09:43AM
Jan-26-23 07:00AM
Jan-09-23 07:00AM
Dec-23-22 04:05PM
Dec-16-22 06:47AM
Dec-12-22 07:30AM
Dec-10-22 10:00AM
Dec-05-22 07:00AM
Nov-22-22 07:30AM
Nov-14-22 08:45AM
07:30AM
Nov-07-22 07:30AM
Nov-04-22 04:30PM
Nov-03-22 09:01AM
Oct-05-22 04:01PM
Sep-23-22 12:00PM
Sep-16-22 04:05PM
Sep-15-22 04:13PM
Sep-14-22 01:26PM
Sep-13-22 04:01PM
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Chee Conley President & CEO Sep 11 '24 Buy 1.71 50,000 85,420 122,504 Sep 12 05:00 PM Haas Jason Chief Financial Officer Sep 12 '24 Buy 1.68 45,344 76,006 124,552 Sep 12 05:00 PM Chee Conley President & CEO Sep 10 '24 Buy 1.51 50,000 75,260 72,504 Sep 12 05:00 PM Haas Jason Chief Financial Officer Sep 10 '24 Buy 1.55 35,363 54,788 59,915 Sep 12 05:00 PM Haas Jason Chief Financial Officer Sep 11 '24 Buy 1.58 19,293 30,446 79,208 Sep 12 05:00 PM Young Richard A Director Jun 28 '24 Sale 5.12 34,837 178,365 8,000 Jul 02 04:15 PM Roth David Chief Medical Officer Apr 03 '24 Sale 4.95 10,451 51,732 0 Apr 05 04:30 PM Roth David Chief Medical Officer Apr 02 '24 Sale 4.98 150 747 10,451 Apr 02 04:58 PM AKKARAJU SRINIVAS Director Dec 21 '23 Buy 4.42 904,977 3,999,998 1,786,427 Dec 26 05:24 PM Roth David Chief Medical Officer Dec 12 '23 Sale 4.95 6,287 31,121 0 Dec 14 04:24 PM Roth David Chief Medical Officer Dec 06 '23 Sale 3.95 6,287 24,834 6,287 Dec 08 04:23 PM
Index -
P/E -
EPS (ttm) -1.43
Insider Own 62.93%
Shs Outstand 55.14M
Perf Week 8.14%
Market Cap 79.33M
Forward P/E -
EPS next Y -0.90
Insider Trans 0.00%
Shs Float 20.45M
Perf Month -8.97%
Income -78.90M
PEG -
EPS next Q -0.28
Inst Own 30.35%
Short Float 27.22%
Perf Quarter -40.81%
Sales 6.31M
P/S 12.57
EPS this Y 37.06%
Inst Trans 0.24%
Short Ratio 17.01
Perf Half Y -59.71%
Book/sh 0.48
P/B 3.02
EPS next Y 20.30%
ROA -39.72%
Short Interest 5.57M
Perf Year -51.66%
Cash/sh 0.84
P/C 1.72
EPS next 5Y -
ROE -129.15%
52W Range 1.22 - 6.30
Perf YTD -52.22%
Dividend Est. -
P/FCF -
EPS past 5Y -48.08%
ROI -57.43%
52W High -77.17%
Beta 1.86
Dividend TTM -
Quick Ratio 2.19
Sales past 5Y 347.21%
Gross Margin 3.80%
52W Low 17.89%
ATR (14) 0.10
Dividend Ex-Date -
Current Ratio 2.19
EPS Y/Y TTM 35.59%
Oper. Margin -1277.05%
RSI (14) 50.51
Volatility 7.17% 5.93%
Employees 94
Debt/Eq 4.83
Sales Y/Y TTM 142.38%
Profit Margin -1249.54%
Recom 1.17
Target Price 10.33
Option/Short Yes / Yes
LT Debt/Eq 4.23
EPS Q/Q 45.15%
Payout -
Rel Volume 0.26
Prev Close 1.42
Sales Surprise 123.20%
EPS Surprise 17.88%
Sales Q/Q 181.16%
Earnings Aug 06 BMO
Avg Volume 327.27K
Price 1.44
SMA20 4.22%
SMA50 -9.54%
SMA200 -45.03%
Trades
Volume 75,891
Change 1.28%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-18-24 Initiated
Raymond James
Outperform
$12
May-25-23 Resumed
Jefferies
Buy
$18 → $15
Dec-08-22 Initiated
H.C. Wainwright
Buy
$11
Sep-23-22 Initiated
Chardan Capital Markets
Buy
$12
Sep-17-24 07:00AM
Aug-14-24 07:00AM
Aug-06-24 01:53PM
08:10AM
07:00AM
06:30AM
Loading…
06:30AM
Jul-29-24 07:00AM
Jul-25-24 08:00AM
Jul-17-24 08:00AM
Jun-24-24 07:00AM
Jun-12-24 07:00AM
May-30-24 07:00AM
May-29-24 07:00AM
May-09-24 07:00AM
May-08-24 07:00AM
02:52PM
Loading…
May-06-24 02:52PM
08:10AM
07:00AM
Apr-25-24 10:02AM
Apr-23-24 07:00AM
Apr-17-24 09:55AM
Apr-09-24 07:00AM
Apr-08-24 08:00AM
Apr-03-24 12:00PM
Mar-28-24 11:54PM
10:25AM
09:15AM
Mar-19-24 08:30AM
Mar-06-24 07:00AM
Jan-09-24 11:01PM
08:44AM
Loading…
08:44AM
Jan-08-24 06:30AM
06:30AM
Jan-05-24 12:55PM
Jan-04-24 06:08PM
04:01PM
(Investor's Business Daily)
10:02AM
08:20AM
06:00AM
05:59AM
Jan-02-24 04:05PM
Dec-04-23 04:00PM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-20-23 04:00PM
Nov-13-23 07:00AM
Nov-09-23 07:00AM
Nov-07-23 04:00PM
Nov-01-23 10:30AM
Oct-31-23 07:00AM
Oct-19-23 10:30AM
Oct-16-23 07:00AM
Oct-11-23 04:00PM
(GlobeNewswire) -12.93%
-6.77%
Oct-04-23 04:00PM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-26-23 07:00AM
Sep-25-23 04:00PM
Sep-21-23 04:00PM
Sep-11-23 06:30AM
Aug-29-23 07:00AM
Aug-05-23 08:05AM
Aug-03-23 05:15PM
04:00PM
Jul-20-23 07:39AM
Jul-18-23 09:43AM
Jul-12-23 07:00AM
Jul-03-23 11:20AM
Jun-22-23 09:18AM
Jun-14-23 11:48AM
Jun-08-23 11:49AM
Jun-06-23 12:13PM
Jun-01-23 07:00AM
May-31-23 08:30AM
07:00AM
May-25-23 09:55AM
May-16-23 06:00AM
May-10-23 07:34AM
May-09-23 09:55AM
May-04-23 08:35AM
07:00AM
Apr-27-23 07:00AM
Apr-13-23 06:33AM
Apr-06-23 04:01AM
Mar-30-23 07:00AM
Mar-17-23 03:35AM
Mar-03-23 05:01AM
Mar-01-23 08:35AM
07:00AM
Feb-23-23 07:00AM
Feb-10-23 04:11AM
Jan-17-23 07:00AM
Dec-08-22 01:24PM
Nov-28-22 09:55AM
Nov-17-22 07:00AM
Nov-15-22 07:00AM
Nov-11-22 09:55AM
Nov-10-22 05:57AM
Nov-08-22 07:00AM
Nov-03-22 07:00AM
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite